SLS Earnings & Financial Statements
SELLAS Life Sciences Group, Inc.
$11.78
-$0.10(-0.84%)
45
Overall
40
Value
50
Tech
47
Quality
Market Cap
$2.40B
Volume
832.12K
52W Range
$1.39 - $15.88
Target Price
$32.50
SLS earnings and financial statements: SELLAS Life Sciences Group, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SLS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $1.00M | $7.60M |
| Cost of revenue | - | - | - | $100.0K | $200.0K |
| Operating income | -$28.27M | -$31.51M | -$37.87M | -$41.95M | -$25.29M |
| EBITDA | -$27.76M | -$30.95M | -$36.84M | -$31.95M | -$20.94M |
| Net income | -$26.90M | -$30.88M | -$37.34M | -$41.30M | -$20.70M |
| EPS (diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $78.34M | $19.43M | $6.22M | $20.94M | $26.27M |
| Total liabilities | $7.47M | $9.97M | $14.20M | $16.09M | $5.93M |
| Shareholders’ equity | $70.87M | $9.46M | -$7.98M | $4.85M | $20.35M |
| Cash and equivalents | $71.79M | $13.89M | $2.53M | $17.13M | $21.36M |
| Long-term debt | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$28.40M | -$35.40M | -$31.41M | -$23.81M | -$26.02M |
| Capital expenditure | - | - | -$5.50M | -$4.50M | - |
| Free cash flow | -$28.40M | -$35.40M | -$36.91M | -$28.31M | -$26.02M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLS | $11.78 | -0.8% | 832.12K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get SELLAS Life Sciences Group, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW